Cancer, 1L Non-small cell lung carcinoma
ORICORIC PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Enozertinib (ORIC-114) in Cancer, 1L Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
5/5/25- Initiate Ph3 trial in 2026. 11/13/25:- Reiterated plan to initiate Ph3 lung cancer trial in 2026. 12/05/25:- Ph1b 1L NSCLC showed 60% confirmed ORR, 100% intracranial ORR; next update Mid-2026. 01/12/26:- Selected Ph3 monotherapy dose; Ph1b 1L EGFR exon20/PACC showed 67–80% ORR, 100% intracranial ORR. 02/23/26:- Reiterated selection of Ph3 monotherapy dose and expectation for multiple 2026 enozertinib data readouts. 05/04/26:- Multiple 2H 2026 1L enozertinib NSCLC data updates planned ahead of potential registrational Phase 3 initiation. 08/03/26:- 1L monotherapy data expected October 2026 and H2 2026 before potential registrational trial.
Verification
Confirm timing and program details against the company announcement or filing.